Evidence map›Paper›PMID 36906080›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2023

Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data.

Rosita van den Puttelaar, Reinier G S Meester, Elisabeth F P Peterse, Ann G Zauber, Jiayin Zheng, Richard B Hayes, Yu-Ru Su, Jeffrey K Lee, Minta Thomas, Lori C Sakoda and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Real-world data and evidence: pioneering frontiers in precision oncology.Journal of Zhejiang University. Science. B · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Reduction in colorectal cancer incidence by screening endoscopy.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Rosita van den PuttelaarDepartment of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: r.vandenputtelaar@erasmusmc.nl.
Reinier G S MeesterDepartment of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Elisabeth F P PeterseDepartment of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Ann G ZauberDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jiayin ZhengPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Richard B HayesDivision of Epidemiology, Department of Population Health, New York University School of Medicine, New York, New York.
Yu-Ru SuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Biostatistics Unit, Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
Jeffrey K LeeDivision of Research, Kaiser Permanente Northern California, Oakland, California; Department of Gastroenterology, Kaiser Permanente San Francisco, San Francisco, California.
Minta ThomasPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Lori C SakodaPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Research, Kaiser Permanente Northern California, Oakland, California.
Yi LiPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Douglas A CorleyDivision of Research, Kaiser Permanente Northern California, Oakland, California; Department of Gastroenterology, Kaiser Permanente San Francisco, San Francisco, California.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Iris Lansdorp-VogelaarDepartment of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Fred Hutch Cancer Center · USErasmus MC · NLKaiser Permanente · USKaiser Permanente Washington Health Research Institute · USMemorial Sloan Kettering Cancer Center · USNew York University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Comparative Modeling of Effective Policies for Colorectal Cancer ControlU01CA253913 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUTTER, CAROLYN M, ZAUBER, ANN GRAHAM · 2020 to 2025
$6.5M
Comparative Modeling of Colorectal Cancer: Informing Health Policies and Prioritizing Future ResearchU01CA199335 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KUNTZ, KAREN M, LANSDORP-VOGELAAR, IRIS · 2015 to 2019
$5.5M
Advancing equity in colorectal cancer genetic risk prediction through expansion of racial/ethnic minority representationR01CA244588 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2020 to 2024
$3.5M
Comprehensive Colorectal Cancer Risk Prediction to Inform Personalized ScreeningR01CA206279 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CORLEY, DOUGLAS ALLEN, HAYES, RICHARD BERNARD · 2017 to 2020
$2.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA206279NCI NIH HHS R01 CA244588NCI NIH HHS U01 CA199335NCI NIH HHS U01 CA253913
6 · The paper itself

Abstract

BACKGROUND &

aimsPrevious studies on the cost-effectiveness of personalized colorectal cancer (CRC) screening were based on hypothetical performance of CRC risk prediction and did not consider the association with competing causes of death. In this study, we estimated the cost-effectiveness of risk-stratified screening using real-world data for CRC risk and competing causes of death.

methodsRisk predictions for CRC and competing causes of death from a large community-based cohort were used to stratify individuals into risk groups. A microsimulation model was used to optimize colonoscopy screening for each risk group by varying the start age (40-60 years), end age (70-85 years), and screening interval (5-15 years). The outcomes included personalized screening ages and intervals and cost-effectiveness compared with uniform colonoscopy screening (ages 45-75, every 10 years). Key assumptions were varied in sensitivity analyses.

resultsRisk-stratified screening resulted in substantially different screening recommendations, ranging from a one-time colonoscopy at age 60 for low-risk individuals to a colonoscopy every 5 years from ages 40 to 85 for high-risk individuals. Nevertheless, on a population level, risk-stratified screening would increase net quality-adjusted life years gained (QALYG) by only 0.7% at equal costs to uniform screening or reduce average costs by 1.2% for equal QALYG. The benefit of risk-stratified screening improved when it was assumed to increase participation or costs less per genetic test.

conclusionsPersonalized screening for CRC, accounting for competing causes of death risk, could result in highly tailored individual screening programs. However, average improvements across the population in QALYG and cost-effectiveness compared with uniform screening are small.

Indexed as

Colorectal NeoplasmsCost-Effectiveness AnalysisAdultAgedAged, 80 and overColonoscopyCost-Benefit AnalysisEarly Detection of CancerHumansMass ScreeningMiddle AgedColorectal CancerCost-EffectivenessEnvironmental RiskGenetic RiskScreening

Identifiers

PMID36906080
PMCPMC10491743
OpenAlexW4323659882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.